北京若生智能科技有限公司
Drug Database
AL

aluminium hydroxide (Pangramin Depot)

✓ Approved

ALK-Abello · 治疗药物

什么是 aluminium hydroxide？

aluminium hydroxide 是一种治疗药物，由ALK-Abello研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Pangramin Depot
公司ALK-Abello
给药途径Injectable (Others), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, ALK-Abello

治疗适应症

aluminium hydroxide 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersRhinitis allergic✓ Approved

相关研究文献

PubMedNature2026-09-10

TRI-611, a selective, brain-penetrant molecular glue degrader of ALK.

Conery Andrew R AR, La Daniel S DS, Alekseyenko Artyom A AA, Marcoux David D et al.

Tyrosine kinase inhibitors (TKIs) targeting anaplastic lymphoma kinase (ALK) have transformed the treatment landscape of ALK fusion-positive non-small-cell lung carcinoma (ALK-positive NSCLC), but the limited options for patients who progress on approved TKIs highlight a continued need for an orthogonal therapeutic approach1,2. TRI-611 is a potent, brain-penetrant molecular glue degrader of ALK fusion proteins with the potential to address this need. TRI-611 promotes the proximity of the ALK kinase domain and CRL4 substrate adaptor CRBN through a unique degron interface distal from the kinase active site. The unique binding interface of TRI-611 leads to selectivity across the proteome including known CRBN neosubstrates and other kinases. TRI-611 treatment induces degradation of all forms of ALK fusion proteins, including wild-type and ALK TKI-resistant versions, leading to regression of cell line and patient-derived subcutaneous and intracranial tumour models of ALK-positive NSCLC. TRI-611 can be combined with orthosteric ALK TKIs, achieving synergistic and durable tumour regressions. TRI-611 represents to our knowledge the first clinical-stage molecular glue degrader targeting an oncogenic gene fusion and has the potential to expand the arsenal of therapeutic options for patients with ALK-positive NSCLC .

PMID 42717093
阅读全文 →
PubMedFrontiers in oncology2026-09-10

Minimal residual disease guides postoperative therapy in a patient with ALK-rearranged adenocarcinoma: a case report.

Xian Xinghong X, Wang Ke K, Wang Liwen L, Ke Hua H

This case report explores the role of circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) monitoring in predicting tumor recurrence or metastasis after consolidative surgery in a patient with ALK-rearranged non-small cell lung cancer (NSCLC). We present a case of a 43-year-old female patient with stage IVA ALK-rearranged NSCLC who initially responded to six months of Alectinib targeted therapy, underwent consolidative surgery with postoperative pathology confirming complete response in the resected primary tumor and lymph nodes, and continued two years of maintenance therapy. During this period, three consecutive MRD tests showed negative results, leading to discontinuation of postoperative therapy. However, two months after stopping Alectinib, the patient developed new brain metastasis in the occipital lobe, necessitating re-initiation of targeted treatment. This case demonstrates the current limitations of ctDNA-based MRD monitoring in reliably predicting recurrence and determining optimal treatment duration in NSCLC. Although MRD monitoring represents an important advancement in NSCLC management, our findings emphasize the need for additional research to validate its clinical applications, particularly in guiding treatment decisions and predicting disease recurrence. The results suggest that larger prospective studies are required to establish evidence-based protocols for MRD monitoring in NSCLC patients.

PMID 42718547
阅读全文 →
PubMedCancer management and research2026-09-10

Multidisciplinary Team Nursing Care During Peri-Transplantation for ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report.

Hong Xiaoying X, Wang Genqun G, Cai Li L, Lin Yuanjiao Y et al.

This case report describes the nursing experience of a patient with ALK‑negative anaplastic large cell lymphoma undergoing autologous hematopoietic stem cell transplantation. A multidisciplinary team model was established, integrating professionals from haematology, rehabilitation, nutrition, psychology to deliver comprehensive peri‑transplant care. An individualized treatment and nursing plan was developed for the peri-transplant period. This plan included pre-transplant physical and psychological preparation, environmental readiness, and management of complications during transplantation, such as infection, bleeding, gastrointestinal symptoms, malnutrition, and depressive mood. Over a 26-day period, successful hematopoietic reconstitution was achieved, and the patient was discharged smoothly from the isolation unit. Post-transplantation, continuous nursing support was provided in infection control, diet, and exercise, along with regular follow-up for two months. The patient's laboratory parameters returned to normal, and both physical and psychological conditions recovered well.

PMID 42719577
阅读全文 →
PubMedJournal of food science2026-09-10

Valorization of Camelina Seed Meal: Ethanolic Ammonium Hydroxide Extraction Coupled With Enzymatic Hydrolysis Enhances Protein Functionality.

Dissanayaka Chandrika Sewwandi CS, Tsao Rong R, Shahidi Fereidoon F

Camelina is an emerging oilseed crop whose deoiled meal has considerable potential as a protein ingredient for food and feed applications. However, its utilization is limited by glucosinolates (GLs), which impart toxicity and undesirable flavors. Although conventional hexane extraction efficiently extracts oil, it retains GLs. Therefore, this study evaluated a novel ammonium hydroxide-ethanol-hexane (NH4OH-EtOH-hexane) extraction system to address the need for effective GL detoxification while simultaneously recovering oil and investigated its effects on the functional properties of protein hydrolysates and peptide fractions compared with conventional hexane extraction. The NH4OH-EtOH-hexane system effectively reduced GL content from 26.08 to 0.89 mg/g (96.6%) and increased crude protein content from 42.65% to 51.76% (21.3%). Following Alcalase hydrolysis and ultrafiltration, protein hydrolysates and peptide fractions from NH4OH-EtOH-hexane-extracted meal exhibited improved functional properties compared with those obtained from hexane-extracted meal, with the <3 kDa fraction showing the most pronounced improvements. Specifically, solubility at pH 7 increased from 83.83% to 92.58% in the protein hydrolysates and from 86.08% to 95.73% in the <3 kDa fraction, while emulsifying stability increased from 24.11 to 40.45 min and from 41.42 to 48.80 min, respectively. These findings demonstrate that NH4OH-EtOH-hexane extraction followed by enzymatic hydrolysis provides an effective strategy for enhancing protein functionality, supporting the valorization of camelina seed meal as a sustainable source of functional protein ingredients.

PMID 42719968
阅读全文 →
PubMedDrug design, development and therapy2026-09-10

Development and Validation of a UPLC-MS/MS Method for Simultaneous Quantification of Ensartinib and Its Major Metabolite M465 in Rat Plasma and Application to Pharmacokinetic Studies.

Jiang Shiqi S, Chen Yan Y, Cao Lu L, Fu Haoxin H et al.

Ensartinib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor approved for the treatment of ALK-positive non-small cell lung cancer (NSCLC). However, its in vivo disposition and metabolic characteristics, particularly those of its major metabolite M465, remain incompletely understood. This study aimed to develop and validate a sensitive ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method for the simultaneous quantification of ensartinib and M465 in rat plasma and to apply the method to a pharmacokinetic study in rats. Crizotinib was used as the internal standard (IS). Plasma samples were processed by one-step protein precipitation with acetonitrile. Chromatographic separation was achieved on a Waters Acquity BEH C18 column using gradient elution with 0.1% formic acid in water and acetonitrile. The method was validated in terms of selectivity, linearity, lower limit of quantification (LLOQ), precision, accuracy, recovery, matrix effect, stability, carry-over and dilution integrity. The validated method was subsequently applied to determine plasma concentrations of ensartinib and M465 after oral administration of ensartinib to rats. The method showed good linearity over the concentration ranges of 0.1-100 ng/mL for ensartinib and 0.05-10 ng/mL for M465, with LLOQs of 0.1 ng/mL and 0.05 ng/mL, respectively. The intra- and inter-day precision values ranged from 2.2% to 16.4%, and the accuracy ranged from -12.3% to 8.0%, meeting the acceptance criteria for bioanalytical method validation. Recovery, matrix effect, stability, carry-over and dilution integrity were all within acceptable limits. After oral administration of ensartinib to rats, the maximum plasma concentrations (Cmax) of ensartinib and M465 were approximately 64.7 ng/mL and 6.3 ng/mL, respectively. The AUC(0-t) values of ensartinib and M465 were 577.6 ng/mL*h and 32.5 ng/mL*h, respectively, indicating lower systemic exposure of M465 compared with the parent drug. A sensitive, reliable, and rapid UPLC-MS/MS method was successfully developed and validated for the simultaneous determination of ensartinib and M465 in rat plasma. The method was successfully applied to a rat pharmacokinetic study and provides useful analytical support for further preclinical investigations of ensartinib and its major metabolite.

PMID 42719333
阅读全文 →
PubMedJPRAS open2026-09-10

Breast implant-associated diffuse large cell B-cell lymphoma (BIA-DLBCL) - a case report and a treatment algorithm.

Borgolte Mahsa Bagheri MB, Sokolow Alexander Jan AJ, Bittner Max-Adrian MA, Schreml Stephan S et al.

Implant-associated lymphomas of the breast are rare. Among breast-implant-associated lymphomas, anaplastic large cell lymphoma (BIA-ALCL) has gained significant attention in recent years and is recognized as a distinct entity. While ALCL is a well-known T-cell lymphoma, there are only a few reports concerning breast-implant-associated B-cell lymphomas. In our report, the lymphoma showed large blasts which were positive for CD20, highly proliferative and associated with Epstein-Barr-Virus. There was no tumor mass present, the cells were seroma associated. BIA-DLCBL has only been known for a few years. They are limited to lymphoma by definition and, unlike DLCBL, BIA-DLCBL is always EBV-positive. A comprehensive evaluation of immunohistochemical markers is crucial for establishing a differential diagnosis between BIA-ALCL and BIA-DLBCL, as overlapping features, particularly CD30 positivity, may lead to misdiagnosis. Other than ALCL, DLCBL typically do not show ALK, CD2, CD3, and other B-cell markers but are positive to CD20, CD5, BCL-2, CD21, CD23, IgD and IgM. This underscores the importance of referring patients to specialized centers to ensure accurate diagnosis and appropriate treatment. The subsequent therapy of BIA-DLCBL should include an en-bloc-resection of the capsule-implant-unit. There is currently no consensus on the optimal therapy for these cases, highlighting the need for further research and expert collaboration We report on a case of breast-implant-associated diffuse large cell B-cell lymphoma and a diagnostic algorithm based on the available data in the literature.

PMID 42718563
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多aluminium hydroxide